<DOC>
	<DOCNO>NCT02896855</DOCNO>
	<brief_summary>This Phase III , randomize , double-blind , placebo-controlled , multicenter clinical trial China evaluate efficacy safety pertuzumab + trastuzumab + docetaxel compare placebo + trastuzumab + docetaxel participant previously untreated HER2-positive MBC .</brief_summary>
	<brief_title>A Study Evaluate Efficacy Safety Pertuzumab + Trastuzumab + Docetaxel Versus Placebo + Trastuzumab + Docetaxel Previously Untreated Human Epidermal Growth Factor Receptor 2 ( HER2 ) -Positive Metastatic Breast Cancer ( MBC )</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Pertuzumab</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Histologically cytologically confirm adenocarcinoma breast locally recurrent metastatic disease suitable chemotherapy HER2positive MBC Left ventricular ejection fraction ( LVEF ) great equal ( &gt; = ) 55 percent ( % ) baseline ( within 42 day randomization ) Eastern Cooperative Oncology Group Performance Status 0 1 Women childbearing potential men agree use effective form contraception continue use duration study treatment least 7 month last dose study treatment ( trastuzumab and/or pertuzumab ) History anticancer therapy MBC ( exception one prior hormonal regimen MBC ) History approve investigative tyrosine kinase/HER inhibitor breast cancer treatment set , except trastuzumab use neoadjuvant adjuvant set History systemic breast cancer treatment neoadjuvant adjuvant set diseasefree interval completion systemic treatment ( exclude hormonal therapy ) metastatic diagnosis le ( &lt; ) 12 month History persistent Grade &gt; = 2 hematologic toxicity result previous adjuvant therapy Grade &gt; = 3 peripheral neuropathy randomization History malignancy within last 5 year , except carcinoma situ cervix nonmelanoma skin carcinoma previously treat curative intent Current clinical radiographic evidence central nervous system ( CNS ) metastases History exposure cumulative dos anthracyclines Current uncontrolled hypertension unstable angina History congestive heart failure ( CHF ) New York Heart Association ( NYHA ) classification , serious cardiac arrhythmia require treatment History myocardial infarction within 6 month randomization History LVEF decrease &lt; 50 % prior trastuzumab neoadjuvant adjuvant therapy Current dyspnea rest due complication advance malignancy , diseases require continuous oxygen therapy Inadequate organ function within 28 day prior randomization Current severe , uncontrolled systemic disease Major surgical procedure significant traumatic injury within 28 day prior study treatment start anticipation need major surgery course study treatment Pregnant lactate woman History receive investigational treatment within 28 day randomization Current know infection human immunodeficiency virus ( HIV ) , hepatitis C virus ( HCV ) , active hepatitis B virus ( HBV ) Receipt intravenous ( IV ) antibiotic infection within 14 day randomization Current chronic daily treatment corticosteroid ( exclude inhale steroid ) Known hypersensitivity protocolspecified study treatment Concurrent participation interventional noninterventional study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>